An official website of the United States government
Abstract BackgroundDelta radiomics is a high‐throughput computational technique used to describe quantitative changes in serial, time‐series imaging by considering the relative change in radiomic features of images extracted at two distinct time points. Recent work has demonstrated a lack of prognostic signal of radiomic features extracted using this technique. We hypothesize that this lack of signal is due to the fundamental assumptions made when extracting features via delta radiomics, and that other methods should be investigated. PurposeThe purpose of this work was to show a proof‐of‐concept of a new radiomics paradigm for sparse, time‐series imaging data, where features are extracted from a spatial‐temporal manifold modeling the time evolution between images, and to assess the prognostic value on patients with oropharyngeal cancer (OPC). MethodsTo accomplish this, we developed an algorithm to mathematically describe the relationship between two images acquired at time and . These images serve as boundary conditions of a partial differential equation describing the transition from one image to the other. To solve this equation, we propagate the position and momentum of each voxel according to Fokker–Planck dynamics (i.e., a technique common in statistical mechanics). This transformation is driven by an underlying potential force uniquely determined by the equilibrium image. The solution generates a spatial‐temporal manifold (3 spatial dimensions + time) from which we define dynamic radiomic features. First, our approach was numerically verified by stochastically sampling dynamic Gaussian processes of monotonically decreasing noise. The transformation from high to low noise was compared between our Fokker–Planck estimation and simulated ground‐truth. To demonstrate feasibility and clinical impact, we applied our approach to18F‐FDG‐PET images to estimate early metabolic response of patients (n = 57) undergoing definitive (chemo)radiation for OPC. Images were acquired pre‐treatment and 2‐weeks intra‐treatment (after 20 Gy). Dynamic radiomic features capturing changes in texture and morphology were then extracted. Patients were partitioned into two groups based on similar dynamic radiomic feature expression via k‐means clustering and compared by Kaplan–Meier analyses with log‐rank tests (p < 0.05). These results were compared to conventional delta radiomics to test the added value of our approach. ResultsNumerical results confirmed our technique can recover image noise characteristics given sparse input data as boundary conditions. Our technique was able to model tumor shrinkage and metabolic response. While no delta radiomics features proved prognostic, Kaplan–Meier analyses identified nine significant dynamic radiomic features. The most significant feature was Gray‐Level‐Size‐Zone‐Matrix gray‐level variance (p = 0.011), which demonstrated prognostic improvement over its corresponding delta radiomic feature (p = 0.722). ConclusionsWe developed, verified, and demonstrated the prognostic value of a novel, physics‐based radiomics approach over conventional delta radiomics via data assimilation of quantitative imaging and differential equations.
more »
« less
This content will become publicly available on September 1, 2026
Development and application of a novel tumor habitat analysis technique based on dynamical modeling
Abstract BackgroundOropharyngeal cancer (OPC) exhibits varying responses to chemoradiation therapy, making treatment outcome prediction challenging. Traditional imaging‐based methods often fail to capture the spatial heterogeneity within tumors, which influences treatment resistance and disease progression. Advances in modeling techniques allow for more nuanced analysis of this heterogeneity, identifying distinct tumor regions, or habitats, that drive patient outcomes. PurposeTo interrogate the association between treatment‐induced changes in spatial heterogeneity and chemoradiation resistance of oropharyngeal cancer (OPC) based on a novel tumor habitat analysis. MethodsA mathematical model was used to estimate tumor time dynamics of patients with OPC based on the applied analysis of partial differential equations. The position and momentum of each voxel was propagated according to Fokker‐Planck dynamics, that is, a common model in statistical mechanics. The boundary conditions of the Fokker‐Planck equation were solved based on pre‐ and intra‐treatment (i.e., after 2 weeks of therapy)18F‐FDG‐PET SUV images of patients (n = 56) undergoing definitive (chemo)radiation for OPC as part of a previously conducted prospective clinical trial. Tumor‐specific time dynamics, measured based on the solution of the Fokker‐Planck equation, were generated for each patient. Tumor habitats (i.e., non‐overlapping subregions of the primary tumor) were identified by measuring vector similarity in voxel‐level time dynamics through a fuzzy c‐means clustering algorithm. The robustness of our habitat construction method was quantified using a mean silhouette metric to measure intra‐habitat variability. Fifty‐four habitat‐specific radiomic texture features were extracted from pre‐treatment SUV images and normalized by habitat volume. Univariate Kaplan‐Meier analyses were implemented as a feature selection method, where statistically significant features (p < 0.05, log‐rank) were used to construct a multivariate Cox proportional‐hazards model. Parameters from the resulting Cox model were then used to construct a risk score for each patient, based on habitat‐specific radiomic expression. The patient cohort was stratified by median risk score value and association with recurrence‐free survival (RFS) was evaluated via log‐rank tests. ResultsDynamic tumor habitat analysis partitioned the gross disease of each patient into three spatial subregions. Voxels within each habitat suggested differential response rates in different compartments of the tumor. The minimum mean silhouette value was 0.57 and maximum mean silhouette value was 0.8, where values above 0.7 indicated strong intra‐habitat consistency and values between 0.5 and 0.7 indicated reasonable intra‐habitat consistency. Nine radiomic texture features (three GLRLM, two GLCOM, and three GLSZM) and SUVmax were found to be prognostically significant and were used to build the multivariate Cox model. The resulting risk score was associated with RFS (p = 0.032). By contrast, potential confounding factors (primary tumor volume and mean SUV) were not significantly associated with RFS (p = 0.286 andp = 0.231, respectively). ConclusionWe interrogated spatial heterogeneity of oropharyngeal tumors through the application of a novel algorithm to identify spatial habitats on SUV images. Our habitat construction technique was shown to be robust and habitat‐specific feature spaces revealed distinct underlying radiomic expression patterns. Radiomic features were extracted from dynamic habitats and used to build a risk score which demonstrated prognostic value.
more »
« less
- Award ID(s):
- 2106988
- PAR ID:
- 10655742
- Publisher / Repository:
- American Association of Physicists in Medicine
- Date Published:
- Journal Name:
- Medical Physics
- Volume:
- 52
- Issue:
- 9
- ISSN:
- 0094-2405
- Format(s):
- Medium: X
- Sponsoring Org:
- National Science Foundation
More Like this
-
-
Objective: Evaluate the effectiveness of machine learning tools that incorporate spatial information such as disease location and lymph node metastatic patterns-of-spread, for prediction of survival and toxicity in HPV+ oropharyngeal cancer (OPC). Materials & methods: 675 HPV+ OPC patients that were treated at MD Anderson Cancer Center between 2005 and 2013 with curative intent IMRT were retrospectively collected under IRB approval. Risk stratifications incorporating patient radiometric data and lymph node metastasis patterns via an anatomically-adjacent representation with hierarchical clustering were identified. These clusterings were combined into a 3-level patient stratification and included along with other known clinical features in a Cox model for predicting survival outcomes, and logistic regression for toxicity, using independent subsets for training and validation. Results: Four groups were identified and combined into a 3-level stratification. The inclusion of patient stratifications in predictive models for 5-yr Overall survival (OS), 5-year recurrence free survival, (RFS) and Radiation-associated dysphagia (RAD) consistently improved model performance measured using the area under the curve (AUC). Test set AUC improvements over models with clinical covariates, was 9 % for predicting OS, and 18 % for predicting RFS, and 7 % for predicting RAD. For models with both clinical and AJCC covariates, AUC improvement was 7 %, 9 %, and 2 % for OS, RFS, and RAD, respectively. Conclusion: Including data-driven patient stratifications considerably improve prognosis for survival and toxicity outcomes over the performance achieved by clinical staging and clinical covariates alone. These stratifications generalize well to across cohorts, and sufficient information for reproducing these clusters is included.more » « less
-
BackgroundMetastatic cancer remains one of the leading causes of cancer-related mortality worldwide. Yet, the prediction of survivability in this population remains limited by heterogeneous clinical presentations and high-dimensional molecular features. Advances in machine learning (ML) provide an opportunity to integrate diverse patient- and tumor-level factors into explainable predictive ML models. Leveraging large real-world datasets and modern ML techniques can enable improved risk stratification and precision oncology. ObjectiveThis study aimed to develop and interpret ML models for predicting overall survival in patients with metastatic cancer using the Memorial Sloan Kettering-Metastatic (MSK-MET) dataset and to identify key prognostic biomarkers through explainable artificial intelligence techniques. MethodsWe performed a retrospective analysis of the MSK-MET cohort, comprising 25,775 patients across 27 tumor types. After data cleaning and balancing, 20,338 patients were included. Overall survival was defined as deceased versus living at last follow-up. Five classifiers (extreme gradient boosting [XGBoost], logistic regression, random forest, decision tree, and naive Bayes) were trained using an 80/20 stratified split and optimized via grid search with 5-fold cross-validation. Model performance was assessed using accuracy, area under the curve (AUC), precision, recall, and F1-score. Model explainability was achieved using Shapley additive explanations (SHAP). Survival analyses included Kaplan-Meier estimates, Cox proportional hazards models, and an XGBoost-Cox model for time-to-event prediction. The positive predictive value and negative predictive value were calculated at the Youden index–optimal threshold. ResultsXGBoost achieved the highest performance (accuracy=0.74; AUC=0.82), outperforming other classifiers. In survival analyses, the XGBoost-Cox model with a concordance index (C-index) of 0.70 exceeded the traditional Cox model (C-index=0.66). SHAP analysis and Cox models consistently identified metastatic site count, tumor mutational burden, fraction of genome altered, and the presence of distant liver and bone metastases as among the strongest prognostic factors, a pattern that held at both the pan-cancer level and recurrently across cancer-specific models. At the cancer-specific level, performance varied; prostate cancer achieved the highest predictive accuracy (AUC=0.88), while pancreatic cancer was notably more challenging (AUC=0.68). Kaplan-Meier analyses demonstrated marked survival separation between patients with and without metastases (80-month survival: approximately 0.80 vs 0.30). At the Youden-optimal threshold, positive predictive value and negative predictive value were approximately 70% and 80%, respectively, supporting clinical use for risk stratification. ConclusionsExplainable ML models, particularly XGBoost combined with SHAP, can strongly predict survivability in metastatic cancers while highlighting clinically meaningful features. These findings support the use of ML-based tools for patient counseling, treatment planning, and integration into precision oncology workflows. Future work should include external validation on independent cohorts, integration with electronic health records via Fast Healthcare Interoperability Resources–based dashboards, and prospective clinician-in-the-loop evaluation to assess real-world use.more » « less
-
PURPOSE: Identify Oropharyngeal cancer (OPC) patients at high-risk of developing long-term severe radiation-associated symptoms using dose volume histograms for organs-at-risk, via unsupervised clustering. MATERIAL AND METHODS: All patients were treated using radiation therapy for OPC. Dose-volume histograms of organs-at-risk were extracted from patients’ treatment plans. Symptom ratings were collected via the MD Anderson Symptom Inventory (MDASI) given weekly during, and 6 months post-treatment. Drymouth, trouble swallowing, mucus, and vocal dysfunction were selected for analysis in this study. Patient stratifications were obtained by applying Bayesian Mixture Models with three components to patient’s dose histograms for relevant organs. The clusters with the highest total mean doses were translated into dose thresholds using rule mining. Patient stratifications were compared against Tumor staging information using multivariate likelihood ratio tests. Model performance for prediction of moderate/severe symptoms at 6 months was compared against normal tissue complication probability (NTCP) models using cross-validation. RESULTS: A total of 349 patients were included for long-term symptom prediction. High-risk clusters were significantly correlated with outcomes for severe late drymouth (p <.0001, OR = 2.94), swallow (p = .002, OR = 5.13), mucus (p = .001, OR = 3.18), and voice (p = .009, OR = 8.99). Simplified clusters were also correlated with late severe symptoms for drymouth (p <.001, OR = 2.77), swallow (p = .01, OR = 3.63), mucus (p = .01, OR = 2.37), and voice (p <.001, OR = 19.75). Proposed cluster stratifications show better performance than NTCP models for severe drymouth (AUC.598 vs.559, MCC.143 vs.062), swallow (AUC.631 vs.561, MCC.20 vs -.030), mucus (AUC.596 vs.492, MCC.164 vs -.041), and voice (AUC.681 vs.555, MCC.181 vs -.019). Simplified dose thresholds also show better performance than baseline models for predicting late severe ratings for all symptoms. CONCLUSION: Our results show that leveraging the 3-D dose histograms from radiation therapy plan improves stratification of patients according to their risk of experiencing long-term severe radiation associated symptoms, beyond existing NTPC models. Our rule-based method can approximate our stratifications with minimal loss of accuracy and can proactively identify risk factors for radiation-associated toxicity.more » « less
-
Glioblastoma (GBM) is highly resistant to treatment and invasion into the surrounding brain is a cancer hallmark that leads to recurrence despite surgical resection. With the emergence of precision medicine, patient-derived 3D systems are considered potentially robust GBM preclinical models. In this study, we screened a library of 22 anti-invasive compounds (i.e., NF-kB, GSK-3-B, COX-2, and tubulin inhibitors) using glioblastoma U-251 MG cell spheroids. We evaluated toxicity and invasion inhibition using a 3D Matrigel invasion assay. We next selected three compounds that inhibited invasion and screened them in patient-derived glioblastoma organoids (GBOs). We developed a platform using available macros for FIJI/ImageJ to quantify invasion from the outer margin of organoids. Our data demonstrated that a high-throughput invasion screening can be done using both an established cell line and patient-derived 3D model systems. Tubulin inhibitor compounds had the best efficacy with U-251 MG cells, however, in ex vivo patient organoids the results were highly variable. Our results indicate that the efficacy of compounds is highly related to patient intra and inter-tumor heterogeneity. These results indicate that such models can be used to evaluate personal oncology therapeutic strategies.more » « less
